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Expression in a recombinant system has been diffi- 
cult to obtain for any of the major fibrillar collagens 
that require processing by eight or more post-transla- 
tional enzymes. Here, two DNA constructs were de- 
signed so that the promoter region of the gene for the 
pro-cYl(1) chain of human type I procollagen drove 
expression of the human type I1 procollagen gene in 
mouse NIH 3T3 cells, a culture line that normally 
synthesizes type I procollagen but not any cartilage- 
specific protein such as type I1 procollagen. Both con- 
structs were expressed as both mRNA and protein. In 
clones expressing the construct at high levels, the 
steady-state  levels of  mRNA and the production of type 
I1 procollagen were comparable to the mRNA levels 
and production  of type I procollagen from the endoge- 
nous mouse genes. Comparison of clones containing the 
two constructs demonstrated that sequences extending 
80 base pairs beyond the major polyadenylation signal 
of the gene are not in themselves sufficient for correct 
termination and 3‘ processing of  RNA transcripts. The 
results strongly suggest that specific sequences present 
in a downstream 3.5-kilobase SphIISphI fragment de- 
termine the termination of the transcription. Of special 
importance is that the system will make it possible to 
examine the consequences of mutations in the human 
type I1 procollagen gene on the processing of RNA 
transcripts and on the functional properties of the pro- 
tein simply by using the genomic DNA from leukocytes 
or other non-cartilaginous sources. 
Expression of many exogenous  genes is readily obtained  in 
a variety of recombinant  host-vector systems. Expression of 
an  exogenous  gene,  however, is difficult to  obtain if the  protein 
normally requires extensive  post-translational processing. Ap- 
parently for this  reason, expression in a recombinant  system 
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has  not  been  reported for any of the major  fibrillar collagens 
that  require processing by eight or more post-translational 
enzymes (1). Rescue experiments in cells that synthesized 
only one of the two chains for type I procollagen were suc- 
cessful in two different systems (2, 3), but synthesis of a 
procollagen molecule in which all three chains are derived 
from an exogenous gene has not been obtained. Failure to 
obtain expression of genes for fibrillar collagens in a fully 
recombinant system has hampered attempts to study the 
normal  structure-function  relationships of the  proteins  and 
to  study  the effects of mutations.  In  particular,  mutations  in 
the gene for type I1 procollagen  have recently been  implicated 
as  the cause of several human diseases (4-13), but because 
adequate numbers of human cartilage cells are difficult to 
obtain and because human chondrocytes readily lose their 
phenotype in culture (14,  15), the  causal  relationship between 
a mutation in the gene and the biological function of the 
protein has proven elusive. Here we describe a system in 
which it  is possible to  express  the  human  type I1 procollagen 
gene in stable transfectants of mouse NIH 3T3 cells. The 
results also indicate  that  correct  termination  and 3’ process- 
ing of RNA  transcripts of the gene require  sequences over 80 
bp’ downstream of the major  polyadenylation signal (16). 
MATERIALS  AND  METHODS 
Gene Constructs-Two versions of a cosmid construct were pre- 
pared.  Both  contained a 5”fragment from the  human  COLlAl gene 
that included the  promoter,  the  first  exon,  and most of the  first  intron 
(Fig. 1). The 5”fragment extended from -500 to +1445 bp of the 
gene (17-19). Both constructs also contained two SphIISphI frag- 
ments of 14  and 12  kb of the  human COL2A1  gene  (20-27). The 5’- 
end of the  14-kb  fragment  corresponded  to  the  3’-end of intron  1B 
(28),  and  the 3’-end of the  12-kb  fragment  extended 80 bp beyond 
the  major  polyadenylation signal of the gene. One construct differed 
from  the  other  in  that  it  contained  an  additional 3.5-kb SphIISphI 
fragment  from  the  3’-end of the gene. 
The  first  construct was assembled  from three  fragments: ( a )  a 2- 
kb  SphIIHindIII  fragment from the  5’-end of human  COLlAl gene 
in which the  SphI  site was converted  to a SalI  site  and  the Hind111 
site was converted  to  an  SphI  site; ( b )  a 14-kb  SphIISphI  fragment 
from the middle of the  human  COL2Al gene; and  (c) a 12-kb  SphI/ 
SphI  fragment  that  extended 80 bp beyond the major  polyadenylation 
signal of the  human  COL2Al gene and  in which the  3’-SphI  site was 
converted  to a SalI  site. The  three  fragments were assembled by four- 
way ligation into  the  SalI  site of the cosmid vector pJB8  that was 
previously  modified  by insertion of a 7-kb  EcoRIIEcoRI  stuffer  frag- 
ment  (27). 
The second construct was assembled in two steps. The first  step 
involved (a) the  5”fragment  from  the  COLlAl gene with  SalIISphI 
terminal  sites used  for the  first  construct  and ( b )  a 3.5-kb SphIISphI 
fragment  that  extended beyond the  3’-end of the COLZA1 gene. The 
3’-SphI site in the 3.5-kb SphIISphI fragment was converted to a 
SalI  site.  In  the  first  step,  the  2-kh  SalIISphI  and 3.5-kb SphIISalI 
fragments were assembled into  the modified  cosmid  vector  by three- 
way ligation. In  the  second  step  the two SphIISphI  fragments of 14 
and 12  kb from  the  COL2Al gene were inserted by three-way ligation 
into  the  SphI  site of the  construct  obtained in the  first  step. 
Cell Transfections-For the cell transfection  experiments, a  cosmid 
clone containing a chimeric  COLlAl/COL2Al gene was cleaved with 
SalI. A plasmid  containing a neomycin-resistent gene (29) was line- 
arized by cleavage with  BamHI.  The two samples were mixed in a 
The abbreviations used  are:  bp,  base pair(s); kb, kilobase(s); 
COLlAl, gene  for the  pro-al(1)  chain of type I procollagen; COLZA1, 
gene for the pro-al(I1) chain of type I1 procollagen; SDS, sodium 
dodecyl  sulfate. 
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ratio of 1O:l of chimeric gene construct  to  neomycin-resistant gene, 
and  the  mixture was then used for co-transfection of NIH 3T3 cells 
t)v calcium phosphate precipitation (30). The DNA in the calcium 
phosphate  solution was  layered onto  cultured cells with  ahout 10 pg 
o f  chimeric  gene construct per 90-mm plate of preconfluent cells. The 
cells were inruhated in Dulhecco's modified Eagle's  medium contain- 
ing 10% newhorn calf serum for 10 h. The samples were subjected  to 
glycerol shock hv adding a 15% glycerol solution for 3 min. The cells 
were transferred to Ihlhecco's modified Eagle's medium cont.aining 
10% newhorn calf serum for 24 h and then to the same medium 
containing 450 pg/ml C.418. Incubation in the medium containing 
G418 was continued for ahout 4 weeks with  a  change of medium every 
third dav. The C418-resistant cells were either pooled or used to 
obtain clones hy isolating foci with a plastic  cylinder  and  subculturing. 
Northrrn Mot and Wrstrrn Hot Anal,v.&-Total RNA was ex- 
tracted from stahlv transfected NIH 3T3 cells  with guanidinium 
isothiocyanate and the RNA purified hv centrifugation in cesium 
chloride (30). The RNA samples were separated hv agarose gel elec- 
trophoresis and hlotted onto nitrocellulose filters for hvhridization 
with human  cDNAs for COL2A1 (31)  and  COLIAl  (32). 
For Western hlot analysis.  the  culture medium from each of several 
clones was removed and separately precipitated hy the addition of 
solid ammonium  sulfate ( 3 0 5  saturation). The precipitates were 
collected hy centrifugation at  14,000 X g and  then dialvzed against  a 
h f f e r  containing 0.15 M NaCI, 0.5 mM EDTA, 0.5 mM N-ethylmal- 
eimide. 0.1 mM p-aminohenzamidine, and 50 mM Tris-HCI  (pH 7.4 
a t  4 "C). Aliquots of the  samples were heated  to 100 "C for 5 min in 
17;) SDS, 50 mM dithiothreitol,  and  10%  (v/v) glycerol, and  separated 
hv electrophoresis on 6% polyacrylamide gels on a mini-gel apparatus 
(Holford SE250, Holford Scientific)  at I25 V for 90 min. The sepa- 
rated proteins were electrohlotted a t  4 0  V for 90 min from the 
polyacrylamide gel onto  a  supported nitrocellulose membrane 
(Schleicher  and  Schuell). The  transferred  proteins were reacted for 
30 min with a 1:500 dilution  (v/v) of a polyclonal antibody specific 
for the  COOH-terminal  telopeptide of human t.ype I1 collagen. The 
antihodv was prepared in rahhits with a 23-residue synthetic  peptide 
that  had  an  amino acid sequence found in the  COOH-terminal 
telopeptide of human t-ype I1 collagen (22). The antibody did not 
react by Western hlot analysis  with  chains of human t.ype I procol- 
Iagen, human  type I collagen, human  type I11 procollagen, or murine 
tvpe I procollagen. The proteins on the filter reacting with the 
antihodv were detected with a secondary anti-rahhit IgG antihodv 
coupled to alkaline phosphatase (Promega Riotec) for 30 min. The 
alkaline  phosphatase was visualized  with NRT/RCIP  (Promega Rio- 
tec) as directed hv the  manufacturer. 
C'ynnogrn Nromidr Prptidr Anal-vsis of T.vpr I I  Col/agrn-Pooled 
samples of medium and cell laver of clones expressing the human 
COI2AI gene were digested at  15 "C wit.h 100 pg/ml pepsin at  pH 
2.0 for 5 h, and  the  proteins were precipitated from the acidic solution 
with 0.8 M NaCI. The pellets were collected hv centrifugation a t  
14,000 X p for 30 min and  resuspended in 0.15 M NaCl in 50 M Tris- 
HCI buffer, pH 7.4, at 4 "C. The proteins were then separated hy 
polvarrvlamide gel electrophoresis in SDS and 6% polyacrylamide 
pels as descrihed above. The gels were equilihrated with 70% (v/v) 
formic acid for 10 min twice and digested with excess CNHr for 90 
lnin at 25 "C. The gels were  placed perpendicularly  to  the  direction 
o f  electrophoresis in the  first  dimension  and  electrophoresed  in  the 
second dimension on polvacrylamide gels (6% stacking gel and  125  
resolving gel) for 90 min. The  separated  peptides were electrohlotted 
onto nitrocellulose membranes for 60 min as described above. The 
peptides were visualized hy reaction  with rahhit polvclonal antihodies 
that recognized multiple epitopes in human t.ype  I1 collagen. The 
antihodies were generouslv  provided hv Dr.  Daniel  Hartmann  (Pas- 
teur  Institute, 1,yon. France).  The  secondary  antihodv was anti-rahhit 
IpC. coupled to  alkaline  phosphatase  (Promega  Hiotec). 
RESULTS AND  DISCUSSION 
The two gene constructs employed here (Fig. 1 )  were de- 
signed to  test  the  hypothesis  that  the  promoter of the  human 
COLlAl gene would drive  expression of human COL2A1  gene 
in mouse NIH  3T3 cells that  normally  express  type I procol- 
lagen but do not synthesize any cartilage-specific proteins 
such as type I1 procollagen. The constructs were used to 
generate  stably  transfected cells, and  the cells  were  assayed 
for synthesis of mRNA for human  type I1 procollagen (Fig. 
2). Cells transfected with either  construct  synthesized  human 
FIG. 1. DNA  constructs  for  expression  of  the human type I1 
procollagen  gene. The 7-kh k,'coIil stuffer was from the  human t>Fe 
I 1  procollagen gene (22, 27). The fhrrr arrolcv indicate the three 
polyadenylation  signals AATAAA. ATTAAA (the major  signal in the 
COL2AI gene),  and AATAAA, respectively. As indicated i n  the  text, 
two  constructs were prepared.  One  contained  the  3.5-kh :I'-.YphI/.Sn\I 
fragment, and the other lacked the 3.5-kh fragment. W. prrmoter. 
exon 1, and intron 1 of COLIAl gene: 0. intrnn 113 t o  exon 5 2  of 
COLZA1 gene; W, 3.5-kh :1'-end of C012A1 gene; El. plR8 rosmid 
vector: 0, 7-kh k,'coRI. 
A B C 
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FIG. 2. Northern blot analysis of mRNA from control and 
transfected  cells. ['and A ,  control RNA from human fetal chontlro- 
cytes (C) (31) and RNA from three cell lines transfected with the 
longer  gene construct  (Fig.  1 ). The filter  was hvhridized with a human 
C01,2A1 cDNA (31). I'anrl R. same RNA as in pond A hyhridized 
with a human COLIAl cDNA ( 3 2 ) .  I'nnrl (', control RNA from 
human fetal chondrocytes  and RNA from two clones containing  the 
shorter gene construct (Fig. 1). The filter WAS hyhridized with the 
same human COL2A1 cDNA as in panr/ A.  The major hands of 
mRNAs in panrls A and R are  about 5 and 5.8 kt). 
type I1 procollagen mRNA.  The  mRNA from cells containing 
the  construct  that included the 3.5-kb SphIISphI fragment 
extending beyond the  3'-end of the gene appeared as a  discrete 
band of the expected  size of about  5  kb (Fig. 2 A ) .  In  contrast, 
the  mRNA from cells containing  the  shorter  construct  (Fig. 
2C) appeared as a broad smear ranging in size from RNAs 
larger  than  the expected message for t-ype I1 procollagen to 
much  smaller sizes. The  results,  therefore,  demonstrated  that 
sequences extending 80 bp beyond the unusual ATTAAA 
major polvadenylation signal (16) of the gene are not in 
themselves  sufficient for correct  termination  and  the 3'-  
processing of RNA transcripts that is required to generate 
stable  mRNA.  The  80-bp region contains  a  GT-rich sequence 
(16) required for correct polyadenylation of transcripts of 
most  eukaryotic genes (33). To  date, specific  sequences that 
determine  the  terminat,ion of t.ranscription in eukaryotic cells 
have not been  defined (33). The  results here strongly suggest 
that  such specific sequences  are  present in the  3.5-kh S p h I /  
SphI fragment of the  human COL2A1 gene. 
The transfected cells were then assayed for expregsion of 
the type I1 procollagen  gene as  protein by Western blot 
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analysis. For  this purpose, a polyclonal antibody was prepared 
in rabbits with a 23-residue synthetic peptide that had an 
amino acid  sequence found  in  the  COOH-terminal  telopeptide 
of human  type I1 collagen (22).  Western  blots  demonstrated 
the presence of human  pro-al(I1)  chains  in  the media from 
several stably  transfected  lines of 3T3 cells (Fig. 3). To  verify 
that  the  transfected cell lines were synthesizing  human  type 
I1 procollagen, two-dimensional cyanogen bromide peptide 
mapping was carried  out (Fig. 4). The  peptides were identified 
by  Western  blotting  with polyclonal antibodies that reacted 
with multiple epitopes  in  the  triple helix of type I1 collagen. 
The  protein  generated  the expected pattern of cyanogen bro- 
mide fragments for type I1 collagen. 
The level of expression of the human COL2Al gene as 
mRNA  and  protein varied in  different  lines  and  clones of the 
neomycin-resistant cells. In  the  highest  expressing clones, the 
steady-state levels of mRNA for type I1 procollagen as  assayed 
with a  cDNA for  the  human  protein were comparable  with 
the endogenous levels of mRNA for  mouse type I procollagen 
as assayed with a cDNA  for  the  human  pro-al(1)  chain.  In 
the  same clones, the  production of human  type I1 procollagen 
was comparable with the production of endogenous mouse 
type I  procollagen as assayed  by semi-quantitative  Western 
blotting  or by chromatographic  purification of the  proteins 
from  culture media (not  shown).  In general, there was  a good 
correlation between the  steady-state levels of mRNA  and  the 
production of type I1 procollagen.  Surprisingly, there were no 
consistent differences in levels of type I1 procollagen produc- 
tion  among  clones  transfected  with  the  shorter  construct  and 
cells transfected  with  the longer construct  containing  the 3.5- 
kb  SphIISphI  fragment.  The longer and  apparently  less  stable 
transcripts  from  the  shorter gene constructs were, therefore, 
efficiently translated. Clones  producing  high  levels of type I1 
procollagen  were stable  and  continued  to  synthesize  the  pro- 
tein even after repeated passage in culture and storage as 
frozen cells over  a  2-year period  (not  shown). 
The results here demonstrate that the promoter region 
together  with  the  first exon and 1,218 bp of the  first  intron 
of the  human  COLlAl gene are  sufficient  to drive  expression 
of a  cartilage-specific  collagen  gene in cells that  do  not  nor- 
1 2 3 4 5  
” 
FIG. 3. Western blot analysis of proteins synthesized by 
individual clones  expressing the human type I1 procollagen 
gene. Proteins from culture media were reduced and separated by 
polyacrylamide gel electrophoresis in SDS and were electroblotted 
onto nitrocellulose  filters. The  filters were reacted  with  the polyclonal 
rabbit  antibodies to a  23-residue synthetic  peptide (described in  the 
text)  that were  specific  for human  type I1 procollagen and collagen. 
The secondary antibody was an anti-rabbit IgG linked to alkaline 
phosphatase. Left lane, type I1 procollagen from human fetal chon- 
drocytes (31). Lane 1 ,  control 3T3 cells that  were not transfected; 
lanes 2-5, clones of 3T3 cells transfected  with  the  shorter  construct 
shown in Fig. 1. 
1 st Dimension .
A B C  
FIG. 4. CNBr peptide analysis of type I1 collagen. Pooled 
samples of medium and cell layer  from  clones  expressing the  human 
t-ype  I1 procollagen  gene were pepsin-digested, salt-precipitated,  and 
separated by polyacrylamide gel electrophoresis in SDS. The gels 
were  digested  with CNBr  and electrophoresed in a  second  dimension. 
The peptides were electroblotted  and visualized  with polyclonal an- 
tibodies that reacted  with multiple  epitopes  in  the  triple helix of type 
I1 collagen. For  comparative purposes,  only  regions containing pep- 
tides from (Y chains are shown. Lane A, control sample of type I1 
collagen from human fetal chondrocytes; lanes B and C, samples from 
two  separate clones stably  transfected with the  shorter gene construct 
shown  in Fig. 1. The control  sample  also  contained a  small amount 
of the  3n  chain of type  XI collagen. 
mally express  any  cartilage gene. The  results,  therefore,  are 
consistent  with previous reports suggesting that  the  promoter 
with or  without  elements  in  the  first  intron is sufficient for 
tissue-specific  expression of the  COLlAl gene (34-38). 
Of special importance is that the system developed here 
provides  a unique  method for obtaining  human  cartilage col- 
lagen  from stably  transfected  murine cells. Extensive  efforts 
were made  in  the  past  to  establish  human  chondrocytes  that 
continue  to  synthesize  type I1 procollagen, but  it is difficult 
to  expand  the  cultures  without a loss of phenotype (14,  15). 
Also, it is usually difficult to obtain sufficient amounts of 
human  articular cartilage. These  technical  limitations have 
presented serious obstacles in developing definitive data to 
confirm  observations suggesting that  mutations in the  type I1 
procollagen gene can  cause several human diseases,  including 
chondrodysplasias (5-7), arthro-ophthalmopathy  (Stickler 
syndrome)  (8-lo),  and  primary generalized osteoarthritis (11- 
13). The  system developed here  makes  it possible to generate 
both  mRNA  and  protein simply  by  using genomic DNA from 
leukocytes or  other  non-cartilaginous sources. Therefore,  it 
makes  it possible to examine  directly  the ffects of mutations 
in  the  human  COL2Al gene on  the processing of RNA tran- 
scripts  and  on  the  functional  properties of type I1 procollagen. 
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